<p>This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,  the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA. </p>

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.

<p>This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,&nbsp; the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.&nbsp;</p>

ASCO 2025 Plenary - MATTERHORN

This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*

Share ASCO 2025 Plenary - MATTERHORN

Sign up to save your podcasts

ASCO 2025 Plenary - MATTERHORN

ASCO 2025 Plenary - MATTERHORN

More shows like Two Onc Docs

NEJM This Week

JAMA Clinical Reviews

Research To Practice | Oncology Videos

ASCO Daily News

Mayo Clinic Talks

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

OncoPharm

ASCO Guidelines

Annals On Call Podcast

The Clinical Problem Solvers

Harrison's PodClass: Internal Medicine Cases and Board Prep

Run the List

Oncology Today with Dr Neil Love

Oncology Brothers: Practice-Changing Cancer Discussions